Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAPHCONTROL
- Development stage
- Preclinical
- Lead developer
- Syngulon
- Modality
- Peptides
01
Overview
STAPHCONTROL is a preclinical-stage antimicrobial drug candidate being developed by Syngulon, a synthetic biology company. It utilizes bacteriocins, which are ribosomally synthesized antimicrobial peptides produced by bacteria, to target and eliminate drug-resistant *Staphylococcus aureus* (including MRSA). The mechanism of action involves bacteriocin-mediated antibacterial activity, which typically functions by disrupting the bacterial cell membrane or interfering with essential intracellular processes. This approach is part of Syngulon's broader effort to develop novel treatments for antimicrobial resistance (AMR) using synthetic biology.
- Other names
- Staphcontrol-Syngulon-bacteriocin
Beyond the preview
Go deeper on STAPHCONTROL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAPHCONTROL.